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Abstract
Background: The impact of implementing the Paris system (TPS) on the rate of dis-
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crepant cases in the negative for high-grade urothelial carcinoma (NHGUC) category
that had a subsequent diagnosis of high-grade urothelial carcinoma (HGUC) on histology is not well studied.
Methods: We adopted TPS in May 2019. We searched discrepant cases with negative urine cytology 2017–2019 in our cyto-histo correlation database. The urine
cytology and follow-up biopsy/resection were reviewed by a cytopathologist who
also did Genitourinary (GU) Pathology subspecialty sign-out. Voided urine and
instrumented urine were included in this study.
Results: There were total of 70 discrepant cases with negative cytology interpretation but HGUC on the subsequent biopsy or resected specimen. Following the TPS
criteria, the rate of discrepant negative cytology cases increased from 6 cases
between January 2017 and May 2019 to 64 cases after May 2019 when we adopted
TPS. There were 2 discrepant negative cases in 2017, 3 cases in 2018, and 65 cases
in 2019. Out of 65 cases in 2019, 64 cases were identified after May 2019. Additional 55 urine cytology slides were reviewed according to the TPS criteria, of which,
the diagnoses remained unchanged in 45 (82%) cases and 10 (19%) cases were
reassigned to either atypical or suspicious categories. The discrepancy was noted
more on the instrumented urine and the upper tract urine. However, the falsenegative rate rose faster in voided urine and lower tract urine. The risk of HGUC with
the category of NHGUC was 0.03% in 2017, 0.05% in 2018, and 1.06% in 2019 at
our institution. The increase in false-negative rate could not be attributed to a single
cytopathologist.
Conclusion: After adopting TPS for reporting urine cytology, there was an increase in
HGUC from negative urine cytology which was subsequently confirmed on histology
as cases of HGUC. The quality control of negative urines could be important monitoring the process when implementing TPS.
KEYWORDS

cyto-histo correlation, false-negative case, false-negative urine, the Paris system for reporting
urinary cytology, TPS
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I N T RO DU CT I O N

Of note, we had 21 practicing cytopathologist during our study
period. We received 7791, 7806, and 7699 urine cytology cases in

Urinary cytology is currently the most common technique used for

2017, 2018, and 2019, respectively; including 6026 (in 2017), 6188

screening and monitoring urothelial carcinoma. It is non-invasive and

(in 2018), and 6342 (in 2019) cases signed out as NHGUC.
The diagnostic criteria for AUC under TPS: (1) Major criterion

cost effective when compared to other modalities. The Paris system
standardized

(required): Non superficial and nondegenerated urothelial cells with an

cytomorphologic criteria and diagnostic categories. Uniform reporting

increased N/C ratio (>0.5). (2) Minor criteria (one required): nuclear

facilitates in patient stratification and the subsequent clinical manage-

hyperchromasia, irregular nuclear membranes, irregular, coarse, and

ment. The principle objective of TPS was to reliably diagnose high-

clumped chromatin.

(TPS)

for

reporting

urinary

cytology

provides

grade urothelial carcinoma (HGUC).1

The diagnostic criteria for HGUC under TPS: (1) Cellularity; at

TPS proposes the following diagnostic categories: (1) unsatisfac-

least 5–10 abnormal cells. (2) N/C ratio: 0.7 or greater. (3) Nucleus:

tory/nondiagnostic; (2) negative for HGUC; (3) atypical urothelial cells

moderate-to-severe hyperchromasia. (4) Nuclear membrane: markedly

(AUC); (4) low-grade urothelial neoplasia; (5) suspicious for HGUC;

irregular. (5) Chromatin: coarse/clumped.

(6) positive for HGUC; and (7) positive for other primary and metastatic malignancies. This reporting system has been adopted worldwide. Multiple studies have been published exploring the advantages
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and disadvantages of the system since its implementation. TPS seems
to have reduced indeterminate diagnosis and improved sensitivity of
2

A total of 70 discrepant cases with negative cytology interpretation

urine cytology reporting . TPS was implemented in our institution in

but high-grade urothelial carcinoma on subsequent biopsy or re-

May 2019. The aim of the study was to evaluate the impact of

section were identified. After adopting TPS for reporting urinary

implementing TPS on the rate of discrepant cases in the negative for

cytology, the rate of discrepant negative cases increased: 6 cases

high-grade urothelial carcinoma (NHGUC) category that had a subse-

January 2017–May 2019 to 64 cases after May 2019 when we

quent diagnosis of high-grade urothelial carcinoma (HGUC) on

adopted TPS. We had 2 discrepant negative cases in 2017, 3 discrep-

histology.

ant cases in 2018, but 65 cases in 2019, of which 64 were after May
2019 (Figure 1).
A total of 55 available urine cytology slides were re-reviewed

2
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MATERIALS AND METHODS

based on the TPS criteria, and the diagnoses remained unchanged
in 45 (82%) cases according to the TPS criteria. 10 (19%) cases

We adopted TPS in May 2019. We searched discrepant cases with

were reassigned to the atypical categories; of which, one case was

negative urine cytology from 2017 to December 2019 in our cyto-

before May 2019. Example discrepant cases that were reassigned

histo correlation database (all cases in this database were reviewed

to the atypical categories are demonstrated in Figure 2. One of the

by different cytotechnologists, fellows, and cytopathologists; a sub-

cases being illustrated in Figure 2 was before TPS (Figure 2A), the

set were presented at intradepartmental consensus meetings if sig-

rest were after TPS (Figure 2B–D), they are representative of the

nificant deviation found). The urine cytology and follow-up biopsy/

findings seen in the bulk of the discrepant cases. Per TPS, an

resection were then re-reviewed by a cytopathologist who also did

increased N/C ratio (>0.5) in nonsuperficial and nondegenerated

Genitourinary (GU) Pathology subspecialty sign-out. ThinPrep was

urothelial cells is a major and required criterion, which is challeng-

used for urine cytologic preparation at our institution. The interval

ing to evaluate in the illustrated cases. Figure 2 A shows a binucle-

between the urine cytology specimens and the subsequent biopsy

ated hyperchromatic cell with coarse chromatin, nuclear groove,

or excision was generally within half a year, on average 1–

and small nucleoli; however, it was a bladder wash, it might be dif-

3 months. Due to TPS is designed for the diagnosis of high-grade

ficult to identify rare diagnostic cells in a very cellular specimen

urothelial carcinoma and the known limitations in the diagnosis of

and assessment for n/c ratio in a binucleated cell is difficult.

other types of urothelial neoplasms and other carcinomas, we

Figure 2B shows a group of urothelial cells with higher n/c ratio

excluded cases with the following final diagnoses on surgical

and enlarged nuclei but they were not well-preserved. Figure 2C is

pathology: urothelial proliferation with uncertain malignant poten-

again an instrumented urine, these groups of urothelial cells are

tial, low-grade urothelial carcinoma, low-grade urothelial carcinoma

small but with seemingly high n/c ratio and focal hyperchromasia,

with focal high-grade features, small cell carcinoma, prostatic ade-

somehow resembling of hyperchromatic crowded groups (HCG) in

nocarcinoma, metastatic carcinoma, and any cases with suspicious

cervical cytology. However, the n/c ratio is difficult to evaluate in

but not definitive diagnoses. We included all specimen types:

a tight group. Figure 2D shows very large glandular appearing cells,

voided urine and instrumented urine including bladder wash, ureter

with small nucleoli and possible cell in cell morphology; however,

wash, ureter brushing, and other types of instrumented urine. We

they do not show hyperchromasia, irregular nuclear contours, or

also investigated whether a single cytopathologist or a few outliers

coarse chromatin, n/c ratio is likely increased but difficult to assess

were responsible for the increase in the false-negative rate by trac-

due to 3D configuration, possible binucleation, or cell in cell

ing back the staff who signed out the individual discrepant cases.

morphology.
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F I G U R E 1 After adopting TPS, the rate of discrepant negative cases increased. Two discrepant negative cases in 2017, 3 discrepant cases in
2018, but 65 cases in 2019, of which 64 were after May 2019 [Color figure can be viewed at wileyonlinelibrary.com]

F I G U R E 2 Representative
discrepant cases. A: Bladder
wash. Initial cytology diagnosis:
NHGUC. Re-review: AUC.
Follow-up biopsy: Flat CIS.
B: Voided urine. Initial cytology
diagnosis: NHGUC. Re-review:
AUC. Transurethral resection:
Non-invasive papillary urothelial
carcinoma, high grade.
C: Instrumented urine. Initial
cytology diagnosis: NHGUC.
Re-review: AUC. Follow-up
resection: Non-invasive papillary
urothelial carcinoma, high grade.
D: Voided urine. Initial cytology
diagnosis: NHGUC. Re-review:
AUC. Follow-up resection:
Invasive papillary urothelial
carcinoma, high grade. The initial
cytology diagnosis is how the
case was signed out initially.
Figure 2A was before TPS era,
Figure 2B–D was after TPS era
[Color figure can be viewed at
wileyonlinelibrary.com]

TABLE 1

The rate of negative, atypical, suspicious, and malignant diagnosis at our institution for urine cytology cases 2017–2019

Urine

Negative

AUC

Suspicious for HGUC

HGUC

2017

6026 (77.3%)

1464 (18.8%)

149 (1.9)

152 (2.0%)

2018

6188 (78.4%)

1536 (19.7%)

29 (0.4%)

121 (1.6%)

2019

6342 (82.4%)

1101 (14.3%)

136 (1.8%)

117 (1.5%)
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TABLE 2

The false negative rate of void urine versus instrumented urine 2017–2019

Urine

Voided

False-negative rate

Instrumented

2017

7089

2 (0.028%)

702

0 (0)

2018

7144

1 (0.014%)

662

2 (0.3%)

2019

7176

523

17 (3.3%)

50 (0.7%)

False-negative rate

Note: The study institution switched to the TPS in May 2019, only one discrepant case identified January–April 2019.

TABLE 3

The false negative rate of upper tract urine versus lower tract urine 2017–2019

Urine

Upper tract

False-negative rate

Lower tract

False-negative rate

2017

221

0

7570

2 (0.03%)

2018

168

1 (0.6%)

7638

2 (0.03%)

2019

185

1 (0.5%)

7514

17 (0.23%)

Note: The study institution switched to the TPS in May 2019, only one discrepant case identified January–April 2019.

TABLE 4

The risk of high-grade urothelial carcinoma with the category of NHGUC 2017-2019

Urine

Negative

2017

6026

2018
2019

False-negative cases

Risk of HGUC with the category of NHGUC

2

0.03%

6188

3

0.05%

6342

67

1.06%

Note: The study institution switched to the TPS in May 2019, only one discrepant case identified January–April 2019.

The rate of negative, atypical, suspicious, and malignant diagnosis

4
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at our institution for urine cytology cases during the years of the
study is shown in Table 1, indicating an increase in negative diagnoses

Urinary cytology was proposed by Papanicolaou and Marshall as a

was at the expense of the atypical category. The discrepancy was

clinically useful method with which to diagnose urothelial cancer in

noted more on the instrumented urine (2018 vs. 2019). However, the

1945.3 Voided urine specimens generally are used in the clinical set-

false-negative rate rose faster in voided urine (50 times) than

ting of hematuria and persistent irritative voiding symptoms, whereas

instrumented urine (11 times) (Table 2). Similarly, the discrepancy was

washing specimens, in conjunction with cystoscopy, are more com-

noted more on the upper tract urine. However, the false-negative rate

monly used in patients with a history of urothelial carcinoma. Urinary

rose faster in lower tract urine (9 times) than upper tract urine (essen-

cytology in general has a higher sensitivity for the diagnosis of HGUC,

tially no change) (Table 3). The risk of HGUC with the category of

which is especially useful for flat carcinomas that may be

NHGUC was 0.03% in 2017, 0.05% in 2018, and 1.06% in 2019 at

cystoscopically occult.

our institution (Table 4). The risk of HGUC with the category of

In 2016, TPS for reporting urinary cytology was created as an

NHGUC increased 20–30 times after implementation of TPS;

international effort to standardize urine cytology.1,4 By placing the

although the risk is still small.

main emphasis on the detection of HGUC, the implementation of TPS

No single cytopathologist was found to be responsible for

has led to a reduction in the rate of indeterminate diagnoses and to

the increase in the false negative rate (Figure 3A). A total of

an increase in the number of positive cases.5–8 It has shown better

4 cytopathologist had discrepant negative cases before and after

concordance with follow-up histology, and thus improves the overall

the implementation of TPS, while the rest 17 cytopathologists

performance and accuracy of urinary cytology.9 However, because

only had discrepant negative cases afterwards (Figure 3B). Analy-

urinary cytology is used primarily for screening purposes, it needs to

sis of the other discrepant cases with negative cytology interpre-

have a high sensitivity and good negative predictive value (NPV) to be

tation but neoplasm or carcinoma other than HGUC, low-grade

an effective test. We therefore performed a 3-year retrospective

urothelial carcinoma, or urothelial proliferations on subsequent

study and found that the rate of false-negative urine had increased

histology revealed one small cell carcinoma (bladder), four pros-

after the implementation of TPS at our institution. Our false-negative

tatic adenocarcinoma, one renal clear cell carcinoma, and one

rate was low at the rate of approximately two to three cases per year

metastatic adenocarcinoma (upper GI/pancreaticobiliary tract)

before the implementation of TPS but reached to 64 cases in the

within the study period.

8-month period right afterwards. These findings suggest that after
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YUAN ET AL.

(A)

F I G U R E 3 A. No single
cytopathologist was found to be
responsible for the increase in the
false-negative rate. B. Four
cytopathologist had discrepant
negative cases before and after
the implementation of TPS, they
had 6 discrepant negative cases in
total before TPS (2- and 1/4-year
period) and 16 discrepant
negative cases in total after TPS
(8-month period). Pathologist #4,
#6, #11, and #12 had 1, 2, 2, and
1 discrepant cases before TPS
and 2, 2, 7, and 5 discrepant cases
after TPS, respectively [Color
figure can be viewed at
wileyonlinelibrary.com]

(B)

implementing TPS at our institution, a subset of cases with “atypical”

implementation of TPS. Their analysis showed a significant increase in

features, including somewhat worrisome for an underlying malig-

urine cytology specificity (12.5–95.9% and 100% in 2016 and 2017,

nancy, were lumped into NHGUC category. On re-review, by applying

respectively) and PPV (83.5% to 96.4% and 100% in 2016 and 2017,

strict TPS criteria, a small portion (19%) of these discrepant cases was

respectively) after switching to TPS. Whereas, the sensitivity and NPV

reassigned to the atypical category while the majority was

gradually decreased, which is consistent with our findings.11 In their

unchanged (82%).

study, the sensitivity was 100% before TPS, this dropped to 87.1% in

Zare et al. reported that applying TPS guidelines increased the

2016 and 81.7% in 2017, respectively, after TPS. Similarly, NPV was

number of NHGUC diagnoses.10 However, the authors argued that

100% before TPS, this dropped to 85.4% in 2016 and 81.4% in 2017,

this finding reflected all the cases with benign/reactive features, as

respectively, after TPS. Notably, the recent study published by Paula

well as all entities with cytologic changes that are not concerning for

R. et al found the overall negative predictive value of TPS for urinary

HGUC were now being classified in the NHGUC category according

cytology was 88.2%; risk of malignancy (ROM) was 11.1% for the cat-

to the TPS. The authors concluded TPS showed slightly better sensi-

egory of “negative for HGUC”.12 Rohilla et al. similarly reported the

tivity (72.5% and 74.5%) and NPV (87% vs. 90%), and thus classifying

risk of HGUC with the category of negative for HGUC was 11.6%.13

more cases as NHGUC by TPS had not raised concern about the sen-

These results indicated roughly 1 in 10 negative urines will be proven

sitivity of urinary cytology. However, this overall slightly improved

to have HGUC on subsequent specimens. Our results indicate the risk

sensitivity and NPV might be resulted from the better performance of

of HGUC with the category of NHGUC was 1.1% in 2019 at our insti-

other categories.

tution. However, we only followed patients for 0–6 months (average

Stanzione et al. performed a retrospective study of 381 cases to
evaluate

the

diagnostic

accuracy

of

urine

cytology

after

1–3 months) and only patients who had a positive biopsy at our institution during that time frame were included in this study.
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It's worth mentioning that the overall sensitivity for urine cytol-

superficial and non-degenerated urothelial cells is a major and

ogy is low in the literature, with various studies reporting values rarely

required criteria, which presents the most challenges when we re-

11-14

Although all patients with gross hematuria should undergo

reviewed the discrepant cases (illustrated in Figure 2). Another limita-

cystoscopy, upper tract imaging, and urinary cytology; it is no longer

tion is that only cases with follow-up surgical pathology were included

recommended to use urine cytology in the initial evaluation of

in the study, the clinical suspicion might be higher in this subset of

patients with microscopic hematuria unless the patient has risk factors

cases. The results may have been affected by the study's limitations.

>80%.

15

for carcinoma in situ. An article by Lee et al.

discussed causes of

Thirdly, an increase in negative diagnoses at the study institution was

false-negative for high-grade urothelial carcinoma in urine cytology.

seemly at the expense of the atypical category rather than the suspi-

They found that the 19 cases with confirmed HGUC was character-

cious/malignant category; one may argue that it is not significant as

ized by eight cases with paucity of candidate tumor cells, four cases

clinicians often treat atypical diagnoses as negative for patient man-

with poor preservation, and six cases with obscuring inflammation/

agement. However, we believe as patients will also be followed by

blood, and one case with interpretation error, with many cases have

urine cytology after surgery or other modalities of treatment, it is

overlapping features. However, these are frequent issues with urine

important that the false-negative rate is being kept low enough to

cytology, which could not explain the increase of false-negative rate

avoid significant number of unexpected findings on the subsequent

after implementing the TPS at our institution.

tests to ensure urine cytology continue to be trusted as an effective

We observed no difference among 21 cytopathologists with dif-

screening test. We suggest that in a case with higher pretest probabil-

ferent levels of experience. The vast majority of our cytopathologists

ity such as a urothelial cancer history, persistent symptoms/abnormal

was cytopathology fellowship trained. No single cytopathologist was

urine analysis despite treatment, abnormal findings on cystoscopy, or

found to be responsible for the increase in the false-negative rate.

extensive degeneration, cases may be managed on a case-by-case

Except for four cytopathologists, all others only had discrepant nega-

basis especially when the n/c ratio is difficult to assess. Since it was

tive cases after TPS. The four cytopathologists who had discrepant

reported that a history of UC and washing specimens had lower

negative cases before and after TPS also showed an upward trend

NPV,20 it is prudent to pay extra attention in these clinical scenarios

after TPS (almost 3 times more discrepant negative cases during the

in an effort to increase the sensitivity and NPV after TPS.

8-month period after TPS comparing to 2- and 1/4-year period before

In summary, adopting TPS for reporting urine cytology results in

TPS). Although we did not study the interobserver variability among

an increase in discrepant negative cases with the subsequent histo-

our cytopathologists, Paris Interobserver Reproducibility Study

logic diagnoses of HGUC at our institution. When implementing TPS,

(PIRST) showed diagnostic categories with the best agreement was

quality control of negative urines could be important monitoring the

NHGUC (71%), followed by low-grade urothelial neoplasm (62%) and

process. Abnormal cystoscopic findings may warrant histologic confir-

HGUC (57%), while practice type (academics versus non-academic)

mation, as a negative urine cytology test cannot confidently eliminate

was not major factors in concordance.16 It was noticed there was a

the possibility of the presence of a high-grade urothelial carcinoma or

5

notable interobserver variability for evaluation of N/C ratio, this is

the presence of a low-grade urothelial carcinoma or other types of

intrinsic to TPS and may not be easily overcome. Although previous

carcinoma such as prostatic adenocarcinoma and metastatic carci-

data supports a N/C ratio cutoff value of 0.5 for atypical urothelial

noma from elsewhere.

cells, the area under the curve (AUC) in this study was 79%,17 a value
that is not optimal as an AUC of 0.5 corresponds to a model that is

DATA AVAILABILITY STAT EMEN T

not better than random and an area of 1 corresponds to perfect pre-

The data that supports the findings of this study are available in the

dictions. Zhang et al reported that morphologists tend to overestimate

supplementary material of this article.

the nuclear-to-cytoplasmic ratio especially for images with an N/C
ratio of 0.4 and 0.6 (> 40.0%); however, the majority of our negative
discrepant cases was felt not meeting the diagnostic criteria of N/C
18

ratio of 0.5 for AUC under re-review.
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Similarly, Layfield et al.

OR CID
Shereen Zia

https://orcid.org/0000-0002-3721-3611

reported that in the critical range, N/C ratio of 0.5 to 0.7, inter-

Sameer Chhetri Aryal

observer correlation (75%), and correlation with true N/C ratio (53%)

Jordan P. Reynolds

https://orcid.org/0000-0001-7203-7951
https://orcid.org/0000-0001-7455-6122

may be insufficiently accurate for precise category assignment in TPS.
One limitation of this study was although the cytology re-review
was blinded to the histologic diagnosis. The case series were composed of negative discrepant cases after histo-cyto correlation; therefore, we knew the cases were upgraded on histology and
correspondingly some of the upgrade from NHGUC form AUC could
be due to retrospective review bias. However, only a small portion of
cases (19%) have been upgraded after re-review, the majority of cases
were not reassigned to a different category, reflecting the issue could
be intrinsic to TPS. Per TPS, an increased N/C ratio (>0.5) in non-
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